Details
Description
Hepatitis C Viral
RNA Quantitative/Qualitative Fluorescence Diagnostic Kit (PCR-Fluorescence Probing)
Hepatitis C virus (HCV) causes both acute and chronic infection. Globally, an estimated 71 million people have chronic hepatitis C infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. Approximately 399 000 people die each year from hepatitis C. mostly from cirrhosis and hepatocellular
Acute HCV infection is usually asymptomatic, few people are diagnosed during the acute phase. In those people who go on to develop chronic HCV infection, the infection is also often undiagnosed because the infection remains asymptomatic until decades after infection when symptoms develop secondary to serious liver damage. It is recommended that HCV serology testing be offered for screening of HCV infection, following which, NAT for HCV RNA should be performed to confirm the infection, assess eligibility for treatment and monitor the antiviral treatment.
Product Performance
- Methodology : Magnetic-bead technology
- Sample Type: Serum, Plasma
- Sample Input Volume : 200 µI
- Genotype Detection: Genotypes 1-6 °
- Linear Range : 50-1 x I 0 1U/ml
- Sensitivity : 25 IU/ml
Features & Advantages
- Simplified RNA Extraction Steps
- Internal Control Monitor
- High Sensitivity of 25 IU/ml
- Full Automation Enabled
Application
- It can be used for accurate and high-sensitivity diagnosis of HCV infection as to raise awareness for timely treatment and transmission prevention.
- It can serve as the reliable basis to assess the stage of HCV infection and eligibility for treatment, as well as the clinical medication guidance to monitor viral load and disease progression for antiviral treatment.
- It can provide modern molecular laboratories with the most advanced combination of turn-around time and throughput with 48/96 samples ( Natch CS I Natch S ) in 3.5 hours.
- It provides the patients with chronic HCV infections with an affordable, accessible and sustainable alternative to monitor virological response during therapy as to guide clinical medication.
